Suchergebnisse - "Patel, Kapilkumar"

PubPharm (11)

1

Mast-cell expressed membrane protein-1 is expressed in classical monocytes and alveolar macrophages in idiopathic pulmonary fibrosis and regulates cell chemotaxis, adhesion, and migration in a TGFβ-dependent manner

enthalten in: American journal of physiology. Cell physiology | 2024

von Perrot, C. | Karampitsakos, T. | Unterman, A. | +9

UpdateOf: bioRxiv. 2023 Oct 10;:. - PMID 37873485

2

A 50-gene high-risk profile predictive of COVID-19 and Idiopathic Pulmonary Fibrosis mortality originates from a genomic imbalance in monocyte and T-cell subsets that reverses in survivors with post-COVID-19 Interstitial Lung Disease

enthalten in: bioRxiv.org | 2023

von Tourki, B. | Jia, M. | Karampitsakos, T. | +17

3

Mast-Cell Expressed Membrane Protein-1 (MCEMP1) is expressed in classical monocytes and alveolar macrophages in Idiopathic Pulmonary Fibrosis and regulates cell chemotaxis, adhesion, and migration in a TGFβ dependent manner

enthalten in: bioRxiv.org | 2023

von Perrot, C. | Karampitsakos, T. | Unterman, A. | +9

4

Mast-Cell Expressed Membrane Protein-1 (MCEMP1) is expressed in classical monocytes and alveolar macrophages in Idiopathic Pulmonary Fibrosis and regulates cell chemotaxis, adhesion, and migration in a TGFβ dependent manner

enthalten in: bioRxiv : the preprint server for biology | 2023

von Perrot, C. | Karampitsakos, T. | Unterman, A. | +9

UpdateIn: Am J Physiol Cell Physiol. 2024 Jan 8;:. - PMID 38189137

5

Successful Treatment of a Patient With Severe COVID-19 Using an Integrated Approach Addressing Mast Cells and Their Mediators

enthalten in: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases | 2022

von Theoharides, T. | Guerra, L. | Patel, K.

6

Aberrant Expression of ACO1 in Vasculatures Parallels Progression of Idiopathic Pulmonary Fibrosis

enthalten in: Frontiers in pharmacology | 2022

von Fukumoto, J. | Lin, M. | Banday, M. | +12

7

Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND) : an open-label extension study

enthalten in: The Lancet. Respiratory medicine | 2021

von Flume, P. | Biner, R. | Downey, D. | +118

ErratumIn: Lancet Respir Med. 2021 Apr;9(4):e38. - PMID 33636124

8

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation : a double-blind, randomised, phase 3 trial

enthalten in: Lancet (London, England) | 2019

von Heijerman, H. | McKone, E. | Downey, D. | +63

CommentIn: Lancet. 2019 Nov 23;394(10212):1886-1888. - PMID 31679947

9

VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles

enthalten in: The New England journal of medicine | 2018

von Keating, D. | Marigowda, G. | Burr, L. | +54

CommentIn: Nat Med. 2019 Jan;25(1):19. - PMID 30617328

10

Addressing inherited predisposition for breast cancer in transplant recipients

enthalten in: Journal of surgical oncology | 2016

von Yang, R. | Kurian, A. | Winton, L. | +4